Vectura and Unilever Ventures announce the spin out of specialty pharmaceutical company Pharmakodex
PharmaKodex is developing a pipeline of improved medicinal products, focusing on re-purposing existing drugs for new indications or combinations, or to provide an improved route of administration. The PharmaKodex development pipeline currently comprises 7 prescription products and 6 OTC products.
PharmaKodex has initiated operations with a strong management team. Chief Executive Officer, Mr Rod Richards, held senior management roles in business and commercial development at Glaxo and SmithKline Beecham, and most recently was CEO at Microscience PLC where he led the business from start up to a successful trade sale in 2005. Prof. John Staniforth, currently Chief Scientific Officer at Vectura, will move to PharmaKodex whilst maintaining a scientific advisory role at Vectura.
Vectura and Unilever Ventures will each retain a significant shareholding in PharmaKodex. Further equity financing will come from specialist venture capital investors.
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.